Alnylam Pharmaceuticals, Inc.ALNYNASDAQ
Loading
R&D Expense Growth TrendStable
Percentile Rank50
3Y CAGR+15.3%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+15.3%/yr
vs -21.0%/yr prior
Acceleration
+36.3pp
Accelerating
Percentile
P50
Within normal range
vs 3Y Ago
1.5x
Solid growth
Streak
1 yr
Consecutive growthStable
| Period | Value |
|---|---|
| 2025 | 17.60% |
| 2024 | 12.13% |
| 2023 | 13.75% |
| 2022 | 11.47% |
| 2021 | 20.97% |
| 2020 | -0.05% |
| 2019 | 29.62% |
| 2018 | 29.38% |
| 2017 | 2.16% |
| 2016 | 38.30% |